ArticleAlcoholism, clinical and experimental research2021

Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial.

John D Roache et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.